Document is current
Any future updates will be listed below
-
Authors
Novella-Navarro, Marta https://orcid.org/0000-0002-2200-0859
Ruiz-Esquide, Virginia https://orcid.org/0000-0002-2657-6601
López-Juanes, Natalia https://orcid.org/0000-0002-1825-2615
Chacur, Chafik Alejandro https://orcid.org/0000-0001-6781-0153
Monjo-Henry, Irene https://orcid.org/0000-0002-3252-8016
Nuño, Laura https://orcid.org/0000-0001-7152-0458
Peiteado, Diana https://orcid.org/0000-0002-6953-409X
Villalba, Alejandro https://orcid.org/0000-0003-2516-3714
Fernández-Fernandez, Elisa https://orcid.org/0000-0002-1628-5042
Sanz-Jardón, María
Kafati, Mónica https://orcid.org/0009-0000-6429-7470
Sanmartí, Raimon https://orcid.org/0000-0002-8864-3806
Plasencia-Rodríguez, Chamaida https://orcid.org/0000-0003-3503-9047
Balsa, Alejandro https://orcid.org/0000-0001-8070-7062
- License Information
-
More Information
Article History
Received: 17 June 2024
Revised: 17 June 2024
Accepted: 11 July 2024
First Online: 16 July 2024
Declarations
:
: This study was approved by the Medical Ethics Committée of La Paz University Hospital, Madrid, Spain: HULP PI-1155 (june 2011) and all patients signed informed consent.
: M Novella-Navarro reports grants from UCB, Galapagos and Lilly outside the submitted work. R. Sanmartí reports grants from Abbvie, Gebro-Pharma, Lilly, MSD, Pfizer, Sanofi and Roche outside the submitted work. C Plasencia-Rodríguez reports grants from Abbvie, Pfizer, Novartis, Lilly and Roche outside the submitted work. A Villalba reports grants form Pfizer, A Balsa reports grants from Abbvie, Amgen, Pfizer, Galapagos, Novartis, Gilead, BMS, Nordic, Sanofi, Sandoz, Lilly, UCB and Roche outside the submitted work. The other authors have declared no competing interests.
